Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Roots Analysis | PRODUCT CODE: 1162465

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1162465

mRNA Therapeutics and mRNA Vaccines Market by Route of Administration, Therapeutic Area, and Geography : Global Trends and Industry Analysis, 2022-2035

PUBLISHED:
PAGES: 330 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

INTRODUCTION

Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. The mRNA encoding instructions for protein synthesis are transferred from a strand of DNA to the ribosomes, where these instructions are translated and processed into functional proteins.

Q1. How is the research and development (R&D) activity evolving in the mRNA-based drugs industry?

mRNA therapeutics and vaccines have emerged as a promising alternative to conventional treatment approaches. Post the onset of the COVID-19 pandemic, mRNA therapeutics and vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, oncological disorders, genetic disorders and other disorders. Subsequently, upon the approval of the first mRNA vaccine under emergency use authorization (EUA), Comirnaty®, in 2020, the field has witnessed a further surge in activity. Since then, two more mRNA-based therapies under EUA, namely (in chronological order of approval year) Spikevax® (December 2020) and GEMCOVAC™-19 (June 2022) have been approved by regulatory authorities. In addition, over 1,000 mRNA therapeutics are being evaluated in various stages of clinical trials for the treatment of multitude of disease indications. This demonstrates remarkable scientific advancement and therapeutic promise of these ground-breaking drug candidates.

Q2. What are the key advantages offered by mRNA therapeutics and vaccines?

The ongoing research and development efforts being undertaken in this domain are primarily being driven by the various advantages offered by these molecules, including higher biological efficacy, enhanced potent immunogenicity and versatile delivery platforms at reduced toxicity levels, over other therapeutic modalities. Recent reports highlight the potential benefits related to the use of mRNA; for instance, such products pose no undesirable risk of inadvertent infection and insertional mutagenesis. Additionally, the in vivo half-life of mRNA can be regulated by deploying different modifications and delivery techniques in order to make the drugs more stable and highly translatable, as it is usually degraded by typical cellular activities. Moreover, owing to the high yields of in vitro transcription reactions, the manufacturing of mRNA candidates is believed to be cost-effective, rapid and scalable.

Q3. What are the current opportunities in the mRNA therapeutics and vaccines market?

In the past few years, the field of mRNA therapeutics and vaccines has evolved at a steady pace. In fact, a significant amount of preclinical data has been gathered and multiple human clinical trials have been initiated. Further, over the past decade, major technological innovations and substantial investments have enabled mRNA to become a promising therapeutic tool in the field of vaccine development and protein replacement therapy. With the advent of several mRNA-based technologies, there has been a rise in the development of these therapeutics to target a myriad of disease indications.

In addition, it is important to highlight the recent opportunities that have been created in this market, post the onset of the COVID-19 pandemic. As mentioned earlier, till date, three mRNA-based vaccines have received approval for the treatment of COVID-19, while a number of such candidates are being evaluated as potential therapies. Moreover, BioNTech and Pfizer have signed contracts to deliver 2.4 billion doses of its approved vaccine, Comirnaty®, by the end of 2022. The overall success of the mRNA-based therapies and vaccines against COVID-19 has attracted the interest of several investors, specifically towards small and emerging mRNA focused biotechnology companies. Further, along with drug developers, the mRNA technology and platform providers are streamlining their existing capabilities to offer a wide range of services to their clients.

Q4. What are the recent developments and expected trends in the mRNA therapeutics and vaccines industry?

Presently, over 35 companies are engaged in the evaluation of more than 195 mRNA therapeutics and vaccines, across various stages of development, for a myriad of disease indications. Further, over the coming decade, several promising leads, specifically those exhibiting enhanced efficacy, are anticipated to be commercially launched. Moreover, considering the active involvement of big pharma players, as well as new entrants, the development pipeline of mRNA drugs is likely to grow further. It is also worth highlighting that close to 150 collaborations have been inked between industry / academic stakeholders to advance the development of their proprietary pipeline candidates. Driven by the growing interest of various stakeholders and encouraging clinical research results, the overall mRNA therapeutics and vaccines market is anticipated to witness consistent growth, till 2035.

Q5. What are the key challenges faced by mRNA drug developers?

Despite the numerous benefits offered by mRNA therapies, developers of these novel products often face challenges related to the stability and targeted delivery of their drug candidates. Some of the other key concerns faced by drug developers include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP). ,

Q6. What are the key value drivers in the mRNA therapeutics and vaccines market?

The key value drivers in the mRNA therapeutics and vaccines market include a significant rise in the overall healthcare expenditure, increased R&D spending, a surge in mRNA-focused research initiatives and a plethora of mRNA technological advancements in the recent past.

Q7. How is the revenue generation potential associated with mRNA therapeutics and vaccines likely to evolve in the coming years?

The revenue generation potential associated with the mRNA therapeutics and vaccines is anticipated to witness a steady growth in the foreseen future. Specifically, in terms of route of administration, the current market is expected to be driven by sales of mRNA therapeutics designed for administration via the intramuscular route, and this trend is unlikely to change in the foreseen future as well. Further, another key segment is represented by mRNA-based therapies targeting infectious diseases, which presently capture a significant share of the global market (in terms of sales-based revenues).

Q8. Who are the key players engaged in the mRNA therapeutics and vaccines market?

Examples of key players engaged in this domain (which have also been captured in this report) include BioNTec, Chimeron Bio, CureVac, eTheRNA, IMMORNA, Moderna, Omega Therapeutics, RNACure and Stemirna Therapeutics.

SCOPE OF THE REPORT

The "mRNA Therapeutics and Vaccines Market (2nd Edition), 2022-2035: Distribution by Route of Administration (Intravenous, Intramuscular, Intranasal and Others), Therapeutic Area (Infectious Diseases, Oncological Disorders and Other Disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa)" report features an extensive study of the current market overview and future potential of the mRNA therapeutics and vaccines market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of mRNA therapeutics and vaccines, based on several relevant parameters, such as phase of development (marketed, phase III, phase II, phase I / II, phase I, preclinical and discovery), type of drug candidate (mRNA therapeutic and mRNA vaccine), therapeutic area (infectious diseases, oncological disorders, genetic disorders, pulmonary disorders, autoimmune disorders and other disorders), type of delivery system used (lipid nanoparticles, lipopolyplex, liposomes, direct transfer, self-amplifying RNA platform and others), type of molecule encoded (spike protein, glycoprotein, antigen, cytokine, protein coding gene, tumor neoantigen, enzyme, tumor antigen and others) and route of administration (intramuscular, intravenous, intranasal and others).
  • A detailed overview of the current market of players engaged in the development of mRNA therapeutics and vaccines, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters, regional landscape and key players engaged in this domain.
  • An in-depth company competitiveness analysis of mRNA therapeutics and vaccines developers based on their portfolio strength (in terms of year of establishment and company size), pipeline strength (in terms of its pipeline maturity and drug administration route) and number of therapeutic areas targeted.
  • Detailed profiles of marketed and late stage (phase III) mRNA therapeutics and vaccines, along with information on the development timeline of the therapy, current development status, primary target indication, therapeutic area, type of molecule encoded, type of delivery system used, affiliated technology, recent partnerships associated with the drug, clinical trial results related to the drug and other recent developmental.
  • A review of the various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring a [A] heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), as well as [B] a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
  • An analysis of start-ups (established between 2016-2022) engaged in this domain, based on several relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, amount raised, number of investors and number of deals inked.
  • An analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, target therapeutic area, study design, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), enrolled patient population and key geographical regions.
  • An analysis of recent collaborations and partnerships within the mRNA therapeutics and vaccines industry, based on several relevant parameters, such as year of partnership, type of partnership, targeted therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2013-2022.
  • A detailed analysis of various investments made by players engaged in this domain, during the period 2013-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings), amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).
  • An in-depth analysis of the various patents that have been filed / granted related to mRNA therapeutics and vaccines domain, since 2016, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical region, CPC symbols, leading industry players (in terms of the number of patents filed / granted) and patent valuation.

One of the key objectives of this report was to estimate the existing market opportunity and the future growth potential of the mRNA therapeutics and vaccines market over the coming years. We have provided an informed estimate on the likely financial evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and upcoming opportunity segmented across important parameters, such as [A] route of administration (intravenous, intramuscular, intranasal and others), [B] therapeutic area (infectious diseases, oncological disorders and other disorders), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

  • Which are the key players engaged in the development of mRNA therapeutics and vaccines?
  • Which mRNA drug candidates are being evaluated across early and late stages of clinical development?
  • Which are the key therapeutic areas targeted by mRNA therapeutics and vaccines?
  • Which type of delivery systems are primarily being used for the delivery of mRNA therapeutics and vaccines?
  • Which are the most active trial sites (in terms of number of clinical studies being conducted) related to mRNA therapeutics and vaccines?
  • Which companies are actively filing patents in order to drive innovation in the field of mRNA therapeutics and vaccines?
  • What type of partnership models are commonly adopted by stakeholders in the mRNA therapeutics and vaccine domain?
  • Which are the companies that are investing heavily in this domain?
  • How is the current and future market opportunity likely to be distributed across the various key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of mRNA therapeutics and vaccines market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to mRNA, featuring insights on the historical evolution of mRNA therapeutics and vaccines. It also presents elaborate description on advantages associated with mRNA therapeutics and vaccines. It also features some of the key applications of both mRNA therapeutics and mRNA vaccines. Additionally, the chapter includes details on the various types of delivery routes and delivery strategies of the mRNA drugs. Further, the chapter discusses the challenges associated with large scale adoption of mRNA therapeutics and vaccines and the associated future perspectives.

Chapter 4 provides a detailed review of the overall market landscape of mRNA therapeutics and vaccines, based on several relevant parameters, such as phase of development (marketed, phase III, phase II, phase I / II, phase I, preclinical and discovery), type of drug candidate (mRNA therapeutic and mRNA vaccine), therapeutic area (infectious diseases, oncological disorders, genetic disorders, pulmonary disorders, autoimmune disorders and other disorders), type of delivery system used (lipid nanoparticles, lipopolyplex, liposomes, direct transfer, self-amplifying RNA platform and others), type of molecule encoded (spike protein, glycoprotein, antigen, cytokine, protein coding gene, tumor neoantigen, enzyme, tumor antigen and others) and route of administration (intramuscular, intravenous, intranasal and others).

Chapter 5 features an elaborate overview of the current market of players engaged in the development of mRNA therapeutics and vaccines, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters, regional landscape and key players engaged in this domain.

Chapter 6 presents an in-depth competitiveness analysis of mRNA therapeutics and vaccines developers based on their portfolio strength (in terms of year of establishment and company size), pipeline strength (in terms of its pipeline maturity and drug administration route) and number of therapeutic areas targeted.

Chapter 7 features detailed profiles of marketed and late stage (phase III) mRNA therapeutics and vaccines, along with information on the development timeline of the therapy, current development status, primary target indication, therapeutic area, type of molecule encoded, type of delivery system used, affiliated technology, recent partnerships associated with the drug, clinical trial results related to the drug and other recent developmental.

Chapter 8 provides a comprehensive review of the various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues in 2021), featuring a [A] heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), as well as [B] a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.

Chapter 9 presents a detailed analysis of start-ups (established between 2016-2022) engaged in this domain, based on several relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, amount raised, number of investors and number of deals inked.

Chapter 10 features an in-depth analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, target therapeutic area, study design, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), enrolled patient population and key geographical regions.

Chapter 11 provides an elaborate discussion and analysis of recent collaborations and partnerships within the mRNA therapeutics and vaccines industry, based on several relevant parameters, such as year of partnership, type of partnership, targeted therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2013-2022.

Chapter 12 features detailed analysis of various investments made by players engaged in this domain, during the period 2013-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings), amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).

Chapter 13 presents an in-depth analysis of the various patents that have been filed / granted related to mRNA therapeutics and vaccines domain, since 2016, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical region, CPC symbols, leading industry players (in terms of the number of patents filed / granted) and patent valuation.

Chapter 14 features a comprehensive market forecast analysis, highlighting the likely growth of the mRNA therapeutics and vaccines market in the short to mid-term and long term, for the period 2022-2035. In order to provide details on the future outlook, our projections have been segmented across important parameters, such as [A] route of administration (intravenous, intramuscular, intranasal and others), [B] therapeutic area (infectious diseases, oncological disorders and other disorders), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).

Chapter 15 is a summary of the entire report. The chapter provides the key takeaways from the report and presents our independent opinion of the mRNA therapeutics and vaccines market, based on the research and analysis described in the previously mentioned chapters.

Chapter 16 is a collection of interview transcripts of the discussions that were held with key stakeholders in the industry.

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which contains a list of companies and organizations mentioned in this report.

Product Code: RA100390

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. mRNA Therapeutics
    • 3.2.1. Advantages of mRNA Therapeutics
    • 3.2.2. Key Applications of mRNA Therapeutics
  • 3.3. mRNA Vaccines
    • 3.3.1. Advantages of mRNA Vaccines
    • 3.3.2. Key Applications of mRNA Vaccines
  • 3.4. mRNA Delivery Routes
  • 3.5. mRNA Delivery Strategies
  • 3.6. Key Challenges Associated with mRNA Therapeutics and Vaccines
  • 3.7. Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. mRNA Therapeutics and Vaccines: Overall Market Overview
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Drug Candidate
    • 4.2.3. Analysis by Therapeutic Area
    • 4.2.4. Analysis by Phase of Development and Therapeutic Area
    • 4.2.5. Analysis by Type of Delivery System Used
    • 4.2.6. Analysis by Type of Molecule Encoded
    • 4.2.7. Analysis by Route of Administration
    • 4.2.8. Analysis by Therapeutic Area and Route of Administration
    • 4.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration (Grid Representation)

5. COMPETITIVE LANDSCAPE

  • 5.1. mRNA Therapeutics and Vaccines: List of Developers
    • 5.1.1. Analysis by Year of Establishment
    • 5.1.2. Analysis by Company Size
    • 5.1.3. Analysis by Location of Headquarters
    • 5.1.4. Key Players: Analysis by Number of Drug Candidates
    • 5.1.5. Key Players: Analysis by Number of Drug Candidates and Phase of Development
    • 5.1.6. Key Players: Analysis by Number of Drug Candidates and Therapeutic Area
    • 5.1.7. Analysis by Year of Establishment, Company Size and Location of Headquarters (Heat Map Representation)
    • 5.1.8. mRNA Therapeutics and Vaccines: Analysis by Phase of Development and Location of Headquarters (Regional Landscape)

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Key Assumptions and Parameters
  • 6.3. Methodology
  • 6.4. mRNA Therapeutics and Vaccines Developers: Company Competitive Analysis
  • 6.5. mRNA Therapeutics and Vaccines Developers based in North America
  • 6.6. mRNA Therapeutics and Vaccines Developers based in Europe
  • 6.7. mRNA Therapeutics and Vaccines Developers based in Asia-Pacific and Rest of the World

7. DRUG PROFILES

  • 7.1. Chapter Overview
  • 7.2. BNT162b2 (BioNTech / Pfizer)
    • 7.2.1. Drug Overview
  • 7.3. GEMCOVAC-19 (Gennova)
    • 7.3.1. Drug Overview
  • 7.4. mRNA-1273 (Moderna)
    • 7.4.1. Drug Overview
  • 7.5. LUNAR-COV19 (Arcturus Therapeutics)
    • 7.5.1. Drug Overview
  • 7.6. CVnCOV (CureVac)
    • 7.6.1. Drug Overview
  • 7.7. mRNA-1010 (Moderna)
    • 7.7.1. Drug Overview
  • 7.8. mRNA-1345 (Moderna)
    • 7.8.1. Drug Overview
  • 7.9. mRNA-1647 (Moderna)
    • 7.9.1. Drug Overview
  • 7.10. ARCoV (Walvax)
    • 7.10.1. Drug Overview

8. BIG PHARMA INITIATIVES

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. mRNA Related Initiatives of Big Pharmaceutical Players
    • 8.3.1. Analysis by Portfolio Diversity
    • 8.3.2. Analysis by Phase of Development
    • 8.3.3. Analysis by Target Therapeutic Areas
  • 8.4. Benchmark Analysis of Big Pharmaceutical Players
    • 8.4.1. Spider Web Analysis: Amgen
    • 8.4.2. Spider Web Analysis: AstraZeneca
    • 8.4.3. Spider Web Analysis: Bayer
    • 8.4.4. Spider Web Analysis: BioNTech
    • 8.4.5. Spider Web Analysis: Eli Lilly
    • 8.4.6. Spider Web Analysis: Gilead Sciences
    • 8.4.7. Spider Web Analysis: GlaxoSmithKline
    • 8.4.8. Spider Web Analysis: Merck
    • 8.4.9. Spider Web Analysis: Moderna
    • 8.4.10. Spider Web Analysis: Novartis
    • 8.4.11. Spider Web Analysis: Novo Nordisk
    • 8.4.12. Spider Web Analysis: Pfizer
    • 8.4.13. Spider Web Analysis: Roche
    • 8.4.14. Spider Web Analysis: Sanofi
    • 8.4.15. Spider Web Analysis: Takeda

9. START-UP HEALTH INDEXING

  • 9.1. Chapter Overview
  • 9.2. Start-ups focused on mRNA Therapeutics and Vaccines
    • 9.2.1. Analysis by Location of Headquarters
  • 9.3. Benchmarking of Start-ups
  • 9.4. Startup-Health Indexing
    • 9.4.1. Analysis by Supplier Strength
    • 9.4.2. Analysis by Pipeline Maturity
    • 9.4.3. Analysis by Pipeline Strength
    • 9.4.4. Analysis by Financial Investments
    • 9.4.5. Analysis by Partnership Activity
    • 9.4.6. Start-ups Health Indexing: Roots Analysis Perspective

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. mRNA Therapeutics and Vaccines: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Status
    • 10.3.3. Analysis by Trial Phase
    • 10.3.4. Analysis by Trial Registration Year and Trial Status
    • 10.3.5. Analysis by Trial Registration Year and Trial Phase
    • 10.3.6. Analysis by Trial Status and Trial Phase
    • 10.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
    • 10.3.8. Analysis by Study Design
    • 10.3.9. Analysis by Type of Sponsor / Collaborator
    • 10.3.10. Most Active Players: Analysis by Number of Registered Trials
    • 10.3.11. Analysis by Therapeutic Area
    • 10.3.12. Analysis by Number of Registered Trials and Geography
    • 10.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
    • 10.3.14. Analysis of Enrolled Patient Population by Geography

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. mRNA Therapeutics and Vaccines: Partnerships and Collaborations
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Analysis by Year and Type of Partnership
    • 11.3.4. Analysis by Therapeutic Area
    • 11.3.5. Analysis by Type of Partnership and Therapeutic Area
    • 11.3.6. Most Active Players: Analysis by Number of Partnerships
    • 11.3.7. Regional Analysis
      • 11.3.7.1. Intercontinental and Intracontinental Agreements
      • 11.3.7.2. Local and International Agreements

12. FUNDING AND INVESTMENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Types of Funding
  • 12.3. mRNA Therapeutics and Vaccines: Funding and Investment
    • 12.3.1. Analysis by Cumulative Year-wise Trend of Funding Instances
    • 12.3.2. Analysis by Cumulative Year-wise Trend of Amount Invested
    • 12.3.3. Analysis by Type of Funding
    • 12.3.4. Analysis by Year and Type of Funding
    • 12.3.5. Analysis of Number of Funding Instances and Amount Invested by Therapeutic Area
    • 12.3.6. Analysis of Number of Funding Instances and Amount Invested by Geography (Continent-wise)
    • 12.3.7. Regional Analysis of Number of Funding Instances (Country-wise)
    • 12.3.8. Most Active Players: Analysis by Number of Funding Instances
    • 12.3.9. Most Active Players: Analysis by Total Amount Raised
    • 12.3.10. Most Active Investors: Analysis by Number of Funding Instances
    • 12.3.11. Analysis of Amount Invested by Year and Type of Funding (Grid Representation)

13. PATENT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. mRNA Therapeutics and Vaccines: Patent Analysis
    • 13.3.1. Analysis by Type of Patent
    • 13.3.2. Analysis by Patent Publication Year
    • 13.3.3. Analysis of Granted Patents by Publication Year
    • 13.3.4. Analysis of Filed Patents by Publication Year
    • 13.3.5. Analysis of Year-wise Filed Patent Applications and Granted Patents
    • 13.3.6. Analysis by Publication Year and Type of Player
    • 13.3.7. Analysis by Patent Issuing Authority
    • 13.3.8. Analysis by Patent Age
    • 13.3.9. Analysis by CPC Symbols
    • 13.3.10. Leading Players: Analysis by Number of Patents
    • 13.3.11. Leading Inventors: Analysis by Number of Patents
  • 13.4. mRNA Therapeutics and Vaccines: Patent Benchmarking Analysis
    • 13.4.1. Analysis by Patent Characteristics
  • 13.5. mRNA Therapeutics and Vaccines: Patent Valuation Analysis

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Global mRNA Therapeutics and Vaccines Market, 2022-2035
    • 14.3.1. mRNA Therapeutics and Vaccines Market: Analysis by Route of Administration
      • 14.3.1.1. mRNA Therapeutics and Vaccines Market for Intravenous Route, 2022-2035
      • 14.3.1.2. mRNA Therapeutics and Vaccines Market for Intramuscular Route, 2022-2035
      • 14.3.1.3. mRNA Therapeutics and Vaccines Market for Intranasal Route, 2022-2035
      • 14.3.1.4. mRNA Therapeutics and Vaccines Market for Other Routes, 2022-2035
    • 14.3.2. mRNA Therapeutics and Vaccines Market: Analysis by Therapeutic Area
      • 14.3.2.1. mRNA Therapeutics and Vaccines Market for Infectious Diseases, 2022-2035
      • 14.3.2.2. mRNA Therapeutics and Vaccines Market for Oncological Disorders, 2022-2035
      • 14.3.2.3. mRNA Therapeutics and Vaccines Market for Other Disorders, 2022-2035
    • 14.3.3. mRNA Therapeutics and Vaccines Market: Analysis by Geography
      • 14.3.3.1. mRNA Therapeutics and Vaccines Market in North America, 2022-2035
      • 14.3.3.2. mRNA Therapeutics and Vaccines Market in Europe, 2022-2035
      • 14.3.3.3. mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035
      • 14.3.3.4. mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035
      • 14.3.3.5. mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035
  • 14.4. mRNA Therapeutics and Vaccines Market: Value Creation Analysis
  • 14.5. mRNA Therapeutics and Vaccines Market: Product-wise Sales Forecasts
    • 14.5.1. COMIRNATY®
      • 14.5.1.1. Target Patient Population
      • 14.5.1.2. Sales Forecast
      • 14.5.1.3. Net Present Value
      • 14.5.1.4. Value Creation Analysis
    • 14.5.2. GEMCOVAC™-19
      • 14.5.2.1. Target Patient Population
      • 14.5.2.2. Sales Forecast
      • 14.5.2.3. Net Present Value
      • 14.5.2.4. Value Creation Analysis
    • 14.5.3. Spikevax®
      • 14.5.3.1. Target Patient Population
      • 14.5.3.2. Sales Forecast
      • 14.5.3.3. Net Present Value
      • 14.5.3.4. Value Creation Analysis
    • 14.5.4. ARCT-154
      • 14.5.4.1. Target Patient Population
      • 14.5.4.2. Sales Forecast
      • 14.5.4.3. Net Present Value
      • 14.5.4.4. Value Creation Analysis
    • 14.5.5. CVnCoV
      • 14.5.5.1. Target Patient Population
      • 14.5.5.2. Sales Forecast
      • 14.5.5.3. Net Present Value
      • 14.5.5.4. Value Creation Analysis
    • 14.5.6. ARCoV
      • 14.5.6.1. Target Patient Population
      • 14.5.6.2. Sales Forecast
      • 14.5.6.3. Net Present Value
      • 14.5.6.4. Value Creation Analysis
    • 14.5.7. mRNA-1647
      • 14.5.7.1. Target Patient Population
      • 14.5.7.2. Sales Forecast
      • 14.5.7.3. Net Present Value
      • 14.5.7.4. Value Creation Analysis
    • 14.5.8. mRNA-1010
      • 14.5.8.1. Target Patient Population
      • 14.5.8.2. Sales Forecast
      • 14.5.8.3. Net Present Value
      • 14.5.8.4. Value Creation Analysis
    • 14.5.9. mRNA-1345
      • 14.5.9.1. Target Patient Population
      • 14.5.9.2. Sales Forecast
      • 14.5.9.3. Net Present Value
      • 14.5.9.4. Value Creation Analysis

15. CONCLUSION

  • 15.1. Chapter Overview

16. INTERVIEW AND SURVEY TRANSCRIPTS

  • 16.1. Chapter Overview
  • 16.2. eTheRNA Immunotherapies
    • 16.2.1. Company Snapshot
    • 16.2.2. Interview Transcript: David Ricketts (Director, Business Development)

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100390

LIST OF TABLES

  • Table 4.1 mRNA Therapeutics and Vaccines: Overall Market Overview
  • Table 4.2 mRNA Therapeutics and Vaccines: Information on Type of Delivery System Used
  • Table 4.3 mRNA Therapeutics and Vaccines: Information on Type of Molecule Encoded
  • Table 4.4 mRNA Therapeutics and Vaccines: Information on Route of Administration
  • Table 5.1 mRNA Therapeutics and Vaccines: List of Developers
  • Table 7.1 Drug Profile: BNT162b2
  • Table 7.2 Drug Profile: GEMCOVAC-19
  • Table 7.3 Drug Profile: mRNA-1273
  • Table 7.4 Drug Profile: LUNAR-COV19
  • Table 7.5 Drug Profile: CVnCoV
  • Table 7.6 Drug Profile: mRNA-1010
  • Table 7.7 Drug Profile: mRNA-1345
  • Table 7.8 Drug Profile: mRNA-1647
  • Table 7.9 Drug Profile: ARCoV
  • Table 9.1 mRNA Therapeutics and Vaccines Start-ups: Information on Location of Headquarters
  • Table 11.1 mRNA Therapeutics and Vaccines: List of Partnerships and Collaborations
  • Table 12.1 mRNA Therapeutics and Vaccines: List of Funding and Investments
  • Table 13.1 Patent Analysis: Top CPC Sections
  • Table 13.2 Patent Analysis: Top CPC Symbols
  • Table 13.3 Patent Analysis: Top CPC Quotes
  • Table 13.4 Patent Portfolio: Summary of Benchmarking Analysis
  • Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 13.6 Patent Analysis: List of Relatively Higher Value Patents
  • Table 14.1 mRNA Therapeutics and Vaccines: Expected Launch Year of Advance Stage Drug Candidates
  • Table 14.2 COMIRNATY®: Target Patient Population
  • Table 14.3 COMIRNATY®: Net Present Value (USD Million)
  • Table 14.4 COMIRNATY®: Value Creation Analysis (USD Million)
  • Table 14.5 GEMCOVAC™-19: Target Patient Population
  • Table 14.6 GEMCOVAC™-19: Net Present Value (USD Million)
  • Table 14.7 GEMCOVAC™-19: Value Creation Analysis (USD Million)
  • Table 14.8 Spikevax®: Target Patient Population
  • Table 14.9 Spikevax®: Net Present Value (USD Million)
  • Table 14.10 Spikevax®: Value Creation Analysis (USD Million)
  • Table 14.11 ARCT-154: Target Patient Population
  • Table 14.12 ARCT-154: Net Present Value (USD Million)
  • Table 14.13 ARCT-154: Value Creation Analysis (USD Million)
  • Table 14.14 CVnCoV: Target Patient Population
  • Table 14.15 CVnCoV: Net Present Value (USD Million)
  • Table 14.16 CVnCoV: Value Creation Analysis (USD Million)
  • Table 14.17 ARCoV: Target Patient Population
  • Table 14.18 ARCoV: Net Present Value (USD Million)
  • Table 14.19 ARCoV: Value Creation Analysis (USD Million)
  • Table 14.20 mRNA-1647: Target Patient Population
  • Table 14.21 mRNA-1647: Net Present Value (USD Million)
  • Table 14.22 mRNA-1647: Value Creation Analysis (USD Million)
  • Table 14.23 mRNA-1010: Target Patient Population
  • Table 14.24 mRNA-1010: Net Present Value (USD Million)
  • Table 14.25 mRNA-1010: Value Creation Analysis (USD Million)
  • Table 14.26 mRNA-1345: Target Patient Population
  • Table 14.27 mRNA-1345: Net Present Value (USD Million)
  • Table 14.28 mRNA-1345: Value Creation Analysis (USD Million)
  • Table 16.1 eTheRNA Immunotherapies: Key Highlights
  • Table 17.1 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
  • Table 17.2 mRNA Therapeutics and Vaccines: Distribution by Type of Drug Candidate
  • Table 17.3 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area
  • Table 17.4 mRNA Therapeutics and Vaccines: Distribution by Phase of Development and Therapeutic Area
  • Table 17.5 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery System Used
  • Table 17.6 mRNA Therapeutics and Vaccines: Distribution by Type of Molecule Encoded
  • Table 17.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
  • Table 17.8 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area and Route of Administration
  • Table 17.9 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment
  • Table 17.10 mRNA Therapeutics and Vaccines Developers: Distribution by Company Size
  • Table 17.11 mRNA Therapeutics and Vaccines Developers: Distribution by Location of Headquarters
  • Table 17.12 Key Players: Distribution by Number of Drug Candidates
  • Table 17.13 Key Players: Distribution by Number of Drug Candidates and Phase of Development
  • Table 17.14 Key Players: Distribution by Number of Drug Candidates and Therapeutic Area
  • Table 17.15 Big Pharma Players: Distribution by Portfolio Diversity
  • Table 17.16 Big Pharma Players: Distribution by Phase of Development
  • Table 17.17 Big Pharma Players: Distribution by Target Therapeutic Areas
  • Table 17.18 Startup-Health Indexing: Distribution by Location of Headquarters
  • Table 17.19 Startup-Health Indexing: Distribution by Supplier Strength
  • Table 17.20 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Table 17.21 Startup-Health Indexing: Distribution by Pipeline Strength
  • Table 17.22 Startup-Health Indexing: Distribution by Financial Investments
  • Table 17.23 Startup-Health Indexing: Distribution by Partnership Activity
  • Table 17.24 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
  • Table 17.25 Clinical Trial Analysis: Distribution by Trial Status
  • Table 17.26 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 17.27 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 17.28 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
  • Table 17.29 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
  • Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Table 17.31 Clinical Trial Analysis: Distribution by Study Design
  • Table 17.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 17.33 Most Active Players: Distribution by Number of Registered Trials
  • Table 17.34 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 17.35 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
  • Table 17.36 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
  • Table 17.37 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Table 17.38 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
  • Table 17.39 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 17.41 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Table 17.43 Most Active Players: Distribution by Number of Partnerships
  • Table 17.44 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 17.45 Partnerships and Collaborations: Local and International Agreements
  • Table 17.46 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
  • Table 17.47 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
  • Table 17.48 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Table 17.49 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 17.50 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Table 17.51 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
  • Table 17.52 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
  • Table 17.53 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
  • Table 17.54 Most Active Players: Distribution by Number of Funding Instances
  • Table 17.55 Most Active Players: Distribution by Total Amount Raised
  • Table 17.56 Most Active Investors: Distribution by Number of Funding Instances
  • Table 17.57 Patent Analysis: Distribution by Type of Patent
  • Table 17.58 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
  • Table 17.59 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
  • Table 17.60 Patent Analysis: Cumulative Distribution of Filed Patents by Publication Year, 2016-2022
  • Table 17.61 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents, 2016-2022
  • Table 17.62 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Player, 2016-2022
  • Table 17.63 Patent Analysis: Distribution by Patent Issuing Authority
  • Table 17.64 Patent Analysis: Distribution by Patent Age
  • Table 17.65 Leading Industry Players: Distribution by Number of Patents
  • Table 17.66 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 17.67 Leading Inventors: Distribution by Number of Patents
  • Table 17.68 Patent Analysis: Valuation Analysis
  • Table 17.69 Global mRNA Therapeutics and Vaccines Market, 2022-2035 (USD Million)
  • Table 17.70 mRNA Therapeutics and Vaccines Market: Distribution by Route of Administration, 2022 and 2035
  • Table 17.71 mRNA Therapeutics and Vaccines Market for Intravenous Route, 2022-2035 (USD Million)
  • Table 17.72 mRNA Therapeutics and Vaccines Market for Intramuscular Route, 2022-2035 (USD Million)
  • Table 17.73 mRNA Therapeutics and Vaccines Market for Intranasal Route, 2022-2035 (USD Million)
  • Table 17.74 mRNA Therapeutics and Vaccines Market for Other Routes, 2022-2035 (USD Million)
  • Table 17.75 mRNA Therapeutics and Vaccines Market: Distribution by Therapeutic Area, 2022 and 2035
  • Table 17.76 mRNA Therapeutics and Vaccines Market for Infectious Diseases, 2022-2035 (USD Million)
  • Table 17.77 mRNA Therapeutics and Vaccines Market for Oncological Disorders, 2022-2035 (USD Million)
  • Table 17.78 mRNA Therapeutics and Vaccines Market for Other Disorders, 2022-2035 (USD Million)
  • Table 17.79 mRNA Therapeutics and Vaccines Market: Distribution by Geography
  • Table 17.80 mRNA Therapeutics and Vaccines Market in North America, 2022-2035 (USD Million)
  • Table 17.81 mRNA Therapeutics and Vaccines Market in Europe, 2022-2035 (USD Million)
  • Table 17.82 mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035 (USD Million)
  • Table 17.83 mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035 (USD Million)
  • Table 17.84 mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035 (USD Million)
  • Table 17.85 COMIRNATY® Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.86 GEMCOVAC™-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.87 Spikevax® Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.88 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.89 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.90 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.91 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.92 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Table 17.93 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Partnerships and Collaborations
  • Figure 2.3 Executive Summary: Funding and Investment Analysis
  • Figure 2.4 Executive Summary: Clinical Trial Analysis
  • Figure 2.5 Executive Summary: Patent Analysis
  • Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Historical Evolution of mRNA
  • Figure 3.2 Key Applications of mRNA Therapeutics
  • Figure 4.1 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
  • Figure 4.2 mRNA Therapeutics and Vaccines: Distribution by Type of Drug Candidate
  • Figure 4.3 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area
  • Figure 4.4 mRNA Therapeutics and Vaccines: Distribution by Phase of Development and Therapeutic Area
  • Figure 4.5 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery System Used
  • Figure 4.6 mRNA Therapeutics and Vaccines: Distribution by Type of Molecule Encoded
  • Figure 4.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
  • Figure 4.8 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area and Route of Administration
  • Figure 4.9 mRNA Therapeutics and Vaccines: Distribution by Phase of Development, Therapeutic Area and Route of Administration
  • Figure 5.1 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment
  • Figure 5.2 mRNA Therapeutics and Vaccines Developers: Distribution by Company Size
  • Figure 5.3 mRNA Therapeutics and Vaccines Developers: Distribution by Location of Headquarters
  • Figure 5.4 Key Players: Distribution by Number of Drug Candidates
  • Figure 5.5 Key Players: Distribution by Number of Drug Candidates and Phase of Development
  • Figure 5.6 Key Players: Distribution by Number of Drug Candidates and Therapeutic Area
  • Figure 5.7 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Figure 5.8 mRNA Therapeutics and Vaccines Developers: Distribution by Phase of Development and Location of Headquarters
  • Figure 6.1 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in North America
  • Figure 6.2 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in Europe
  • Figure 6.3 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in Asia-Pacific and Rest of the World
  • Figure 8.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies
  • Figure 8.2 Big Pharma Players: Distribution by Portfolio Diversity
  • Figure 8.3 Big Pharma Players: Distribution by Phase of Development
  • Figure 8.4 Big Pharma Players: Distribution by Target Therapeutic Areas
  • Figure 8.5 Spider Web Analysis: Amgen
  • Figure 8.6 Spider Web Analysis: AstraZeneca
  • Figure 8.7 Spider Web Analysis: Bayer
  • Figure 8.8 Spider Web Analysis: BioNTech
  • Figure 8.9 Spider Web Analysis: Eli Lilly
  • Figure 8.10 Spider Web Analysis: Gilead Sciences
  • Figure 8.11 Spider Web Analysis: GlaxoSmithKline
  • Figure 8.12 Spider Web Analysis: Merck
  • Figure 8.13 Spider Web Analysis: Moderna
  • Figure 8.14 Spider Web Analysis: Novartis
  • Figure 8.15 Spider Web Analysis: Novo Nordisk
  • Figure 8.16 Spider Web Analysis: Pfizer
  • Figure 8.17 Spider Web Analysis: Roche
  • Figure 8.18 Spider Web Analysis: Sanofi
  • Figure 8.19 Spider Web Analysis: Takeda
  • Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
  • Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
  • Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Strength
  • Figure 9.5 Startup-Health Indexing: Distribution by Financial Investments
  • Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
  • Figure 9.7 Start-up Health Indexing: Roots Analysis Perspective
  • Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
  • Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 10.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
  • Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
  • Figure 10.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Figure 10.8 Clinical Trial Analysis: Distribution of Trials by Study Design
  • Figure 10.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 10.10 Most Active Players: Distribution by Number of Registered Trials
  • Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 10.12 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
  • Figure 10.13 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
  • Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
  • Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 11.4 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 11.5 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Figure 11.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 11.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 11.8 Partnerships and Collaborations: Local and International Agreements
  • Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
  • Figure 12.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
  • Figure 12.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 12.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Figure 12.6 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
  • Figure 12.7 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
  • Figure 12.8 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
  • Figure 12.9 Most Active Players: Distribution by Number of Funding Instances
  • Figure 12.10 Most Active Players: Distribution by Total Amount Raised
  • Figure 12.11 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 12.12 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding
  • Figure 13.1 Patent Analysis: Distribution by Type of Patent
  • Figure 13.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
  • Figure 13.3 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
  • Figure 13.4 Patent Analysis: Cumulative Distribution of Filed Patents by Publication Year, 2016-2022
  • Figure 13.5 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents, 2016-2022
  • Figure 13.6 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Player, 2016-2022
  • Figure 13.7 Patent Analysis: Distribution by Patent Issuing Authority
  • Figure 13.8 Patent Analysis: Distribution by Patent Age
  • Figure 13.9 Patent Analysis: Distribution by CPC Symbols
  • Figure 13.10 Leading Industry Players: Distribution by Number of Patents
  • Figure 13.11 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 13.12 Leading Inventors: Distribution by Number of Patents
  • Figure 13.13 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
  • Figure 13.14 Patent Analysis: Valuation Analysis
  • Figure 14.1 Global mRNA Therapeutics and Vaccines Market, 2022-2035 (USD Million)
  • Figure 14.2 mRNA Therapeutics and Vaccines Market: Distribution by Route of Administration, 2022 and 2035
  • Figure 14.3 mRNA Therapeutics and Vaccines Market for Intravenous Route, 2022-2035 (USD Million)
  • Figure 14.4 mRNA Therapeutics and Vaccines Market for Intramuscular Route, 2022-2035 (USD Million)
  • Figure 14.5 mRNA Therapeutics and Vaccines Market for Intranasal Route, 2022-2035 (USD Million)
  • Figure 14.6 mRNA Therapeutics and Vaccines Market for Other Routes, 2022-2035 (USD Million)
  • Figure 14.7 mRNA Therapeutics and Vaccines Market: Distribution by Therapeutic Area, 2022 and 2035
  • Figure 14.8 mRNA Therapeutics and Vaccines Market for Infectious Diseases, 2022-2035 (USD Million)
  • Figure 14.9 mRNA Therapeutics and Vaccines Market for Oncological Disorders, 2022-2035 (USD Million)
  • Figure 14.10 mRNA Therapeutics and Vaccines Market for Other Disorders, 2022-2035 (USD Million)
  • Figure 14.11 mRNA Therapeutics and Vaccines Market: Distribution by Geography
  • Figure 14.12 mRNA Therapeutics and Vaccines Market in North America, 2022-2035 (USD Million)
  • Figure 14.13 mRNA Therapeutics and Vaccines Market in Europe, 2022-2035 (USD Million)
  • Figure 14.14 mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035 (USD Million)
  • Figure 14.15 mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035 (USD Million)
  • Figure 14.16 mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035 (USD Million)
  • Figure 14.17 COMIRNATY® Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.18 GEMCOVAC™-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.19 Spikevax® Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.20 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.21 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.22 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.23 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.24 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 14.25 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)
  • Figure 15.1 Concluding Remarks: Overall Market Landscape
  • Figure 15.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 15.3 Concluding Remarks: Funding and Investment Analysis
  • Figure 15.4 Concluding Remarks: Clinical Trial Analysis
  • Figure 15.5 Concluding Remarks: Patent Analysis
  • Figure 15.6 Concluding Remarks: Market Forecast and Opportunity Analysis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!